Wells Fargo Maintains Overweight on HeartFlow, Raises Price Target to $39

Late Breaking Data from Independent Government-Funded Trial at ESC Shows Heartflow FFRCT Analysis Reduces Unnecessary Invasive Heart Procedures by Nearly Half

Heartflow announced one-year results from the independent FUSION trial showing its FFRCT Analysis reduced unnecessary invasive heart procedures by 44% when added to standard CCTA scans. The Dutch government-funded randomized controlled trial of 528 patients demonstrated that Heartflow's AI technology safely bridges diagnostic gaps in coronary artery disease evaluation, maintaining identical revascularization rates while significantly reducing diagnostic catheterizations.

Heartflow FFRCT Analysis Sustains 44% Reduction In Unnecessary Invasive Angiography At One Year, FUSION Trial Confirms

HeartFlow Shares Soar Following Strong Q2 Results and Upgraded Guidance

HeartFlow shares are surging Friday after it reported better-than-expected Q2 adjusted EPS results and raised its full-year outlook.

Canaccord Genuity Maintains Buy on HeartFlow, Raises Price Target to $45

Canaccord Genuity analyst William Plovanic maintains HeartFlow (NASDAQ:HTFL) with a Buy and raises the price target from $37 to $45.